MAPS’ mission is to treat conditions for which conventional medicines provide limited relief, such as PTSD & anxiety associated with life-threatening illnesses, by developing psychedelics & marijuana into prescription medicines.
MDMA Psychotherapist Training Study Begins:
MAPS E-Mail Newsletter

April 15, 2011
Dear xxxx,
It’s an honor to bring you the April 2011 edition of the MAPS E-mail Newsletter.

We’ve come a long way in the last 25 years. The challenge is no longer convincing regulatory agencies of the value of our research, but finding the financial resources to conduct the massive Phase 3 studies—involving scores of therapists and hundreds of subjects in multiple countries—required to make MDMA-assisted psychotherapy a legally available treatment for those who need it most.

Another challenge as we get ready to graduate to the next phase of our drug development program will be finding individuals with the skills and expertise required to conduct experimental MDMA-assisted psychotherapy sessions. That’s why the FDA is allowing us to conduct a training study for psychedelic therapists, in the form of a basic investigation of the effects of MDMA-assisted psychotherapy on healthy volunteers. This study is now screening its first participant.

With your help, MAPS is building the foundation for the future of psychedelic medicine.

We need your support to turn psychedelics and marijuana into prescription medicines.
 Make a Contribution
On Saturday, April 16, the fourth subject will receive his first experimental treatment session in our Phase 2 study of MDMA-assisted psychotherapy for PTSD in veterans of war. For this subject, as for many other patients, conventional pharmaceutical and psychotherapeutic approaches to helping him overcome his traumatic memories have failed. For him, this treatment is a chance for a fresh start. At the same time, he is contributing to the fast-growing body of scientific data required to make MDMA available as a prescription medicine for thousands—and possibly millions—like him.

Just yesterday, in recognition of the pressing need for this research, an anonymous donor made a gift to MAPS of $100,000. This contribution will go a long way toward completing our current MDMA/PTSD study and advancing our ever-growing range of projects. You don’t have to be a millionaire to make a difference—but it helps.

Last month, I reminded you about our “Watch, Learn, and Share” video campaign, for which a donor gave us $1 every time you viewed a video from our 2010 Psychedelic Science conference, up to a generous $15,000. At the time, we were just 2,000 views short of our goal. Since the start of the campaign, our conference videos have now received over 19,000 views and earned MAPS every penny of the $15,000 offered—thanks to your commitment to psychedelic science and to your choice to support MAPS.

Just because the campaign is over doesn’t mean you’ve missed your chance. Health practitioners can still watch the videos to earn professional credit through our co-sponsor at the Spiritual Competency Resource Center. Of course, you can always just watch them for fun, too.

Please enjoy and share this edition of the MAPS E-mail Newsletter. And also, remember that none of these accomplishments—not even this newsletter—would have been possible without your support. Whether it’s a little or a lot, please donate today and help make sure the good news keeps rolling in.

Oh, and one more thing: Get ready to commemorate 25 years of psychedelic and medical marijuana research and education by joining us for a conference, workshops, and benefit celebration from December 9-11, 2011, in the San Francisco Bay Area. You won’t want to miss this.


Brad Burge, M.A.
MAPS Director of Communications

Be Aware,

Crackbillionair (,